Statistics for Dual therapy (ritonavir boosted atazanavir+raltegravir) versus standard triple therapy (ritonavir boosted atazanavir+tenofovir/emtricitabine) in patients failing first line therapy: 48 week results from a randomized pilot study
Total visits
| views | |
|---|---|
| Dual therapy (ritonavir boosted atazanavir+raltegravir) versus standard triple therapy (ritonavir boosted atazanavir+tenofovir/emtricitabine) in patients failing first line therapy: 48 week results from a randomized pilot study | 5 |
Total visits per month
| views | |
|---|---|
| mayo 2024 | 4 |
| junio 2024 | 0 |
| julio 2024 | 1 |
| agosto 2024 | 0 |
| septiembre 2024 | 0 |
| octubre 2024 | 0 |
| noviembre 2024 | 0 |
File Visits
| views | |
|---|---|
| 10.1016j.ijid.2018.04.3476.pdf | 4 |